Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on May 29, 2007


US20070117842 is a polymorph application, and there’s been a fair amount of IP activity around the compound. Indications are its E7080: an oral PhI Vegf, FGF, Pdgf, C-Kit, etc compound which first touched down in WO/2004/080462.


2 Responses to “E7080”

  1. polymorph application…you mean they are patenting a polymorph of an already patented compound? didn’t know about this.

  2. kinasepro said

    Ayyep, It has become a common practice of process groups. Different crystal forms can have different dissolution properties, and thus different pk. It might have something to do with extending the patent life, but I think its more to do with preventing others from attempting to claim they’ve found a better version of your drug.

    For KP its pretty good evidence that if a group went to all the trouble to find the best crystal form of a specific compound – its probably the one in the clinic.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: